Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinoma

NCT05385861 is registered in ClinicalTrials.gov with National Health Research Institutes, Taiwan as lead sponsor.

NCT NCT05385861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05385861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinoma
Lead sponsor
National Health Research Institutes, Taiwan
Phase
Phase 1/2
Overall status
Enrolling by invitation
Start date
August 14, 2025
Completion date
December 31, 2025
Enrollment
52 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

gep-net